Evaluate Vantage's coverage of the Ash 2021 congress.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Novartis unveils the first clinical backing for a two-day manufacturing technique that it hopes will recharge its Car-T efforts.
SAR445136 could take on Crispr and Vertex’s CTX001, but plenty of other groups have the same idea.
Data in sickle cell disease look encouraging, but a filing is a way away.
November approval decisions loom for cilta-cel and Voxzogo, while molnupiravir heads for an advisory panel.
Proof-of-concept data at Ash should give clues about whether GBT021601 could be an oral functional cure for sickle cell disease.
The young biotech is well placed to deliver its first pivotal win, but investor focus might lie elsewhere.
Fibrogen’s controversial anaemia pill becomes the latest example of markedly different regulatory stances taken in Europe and the US.